Bayer Schering Abandons Higher Dose Betaferon Following Disappointing Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Head-to-head trial against Teva’s Copaxone in MS failed to show statistically significant superiority.
You may also be interested in...
High Copaxone Dose Fails To Show Superiority In MS, Teva Says
In Phase III, 40 mg dose did not reduce relapse rate in patients over the approved 20 mg strength.
High Copaxone Dose Fails To Show Superiority In MS, Teva Says
In Phase III, 40 mg dose did not reduce relapse rate in patients over the approved 20 mg strength.
Genzyme/Bayer Report Positive Top-Line Phase II MS Data For Campath
Clinical hold on the Phase II trial was lifted “within the last six months” and dosing completed, Genzyme’s Enyedy says.